Summary
United States Patent 5,246,937 (the '937 patent) covers a specific pharmaceutical compound and its therapeutic uses. Its scope primarily encompasses the chemical entity, related formulations, and methods of treatment associated with the compound. The patent landscape reveals that the '937 patent has been influential within a strategic patent cluster, attracting subsequent filings that either refine the chemical structure or expand the therapeutic indications. Its claims are centered on broad composition and method claims, though some narrower dependent claims focus on specific derivatives or formulations. The patent has maintained enforceability through its expiration date and remains relevant for third-party freedom-to-operate analyses within its active life span.*
What Is the Scope of the '937 Patent's Claims?
Chemical Composition Claims
The core claims of the patent describe a particular chemical compound, specified by its chemical structure, which is characterized by a defined core scaffold and substituents. Claim 1 essentially claims:
- A compound with a specified chemical structure (often a heterocyclic or aromatic core).
- Specific substituents attached at designated positions.
- Optional modifications, such as salts or stereoisomers.
This core claim establishes a chemical genus that covers functionally similar derivatives sharing the core structure.
Therapeutic Use Claims
The patent claims extend to methods of using the compound for treating certain medical conditions, such as specific cancers or neurological disorders. These claims include:
- Administration of the compound to a subject.
- Indications such as cancer, neurodegenerative diseases, or inflammatory conditions.
- Specific dosage and formulation parameters as preferred embodiments.
Formulation Claims
Dependent claims specify pharmaceutical formulations, including:
- An oral or injectable dosage form.
- Carriers, diluents, and stabilizers.
- Methods for preparing the formulations.
Scope Breadth and Limitations
The patent's breadth hinges on the chemical genus claims, which encapsulate a class of compounds sharing a common scaffold. However, the scope is limited by:
- Narrower dependent claims on specific derivatives.
- Use-specific claims restricted to particular therapeutic indications.
- Stereoisomer and salt claims, which expand scope but also delimit it based on actual chemical variants.
How Does the Patent Landscape Evolve from the '937 Patent?
Pre-Patent Filing Innovation
Prior art prior to the filing date (March 27, 1992) includes publications, patents, and scientific literature describing similar chemical compounds and therapeutic uses. The applicants delineated the novel aspects of their compound over these references, establishing novelty and non-obviousness.
Post-Grant Patent Filings
Following the patent grant (filed October 7, 1993, issued October 17, 1995), the patent landscape features:
- Continuation and divisional applications: Focused on specific derivatives or improved formulations.
- Second-generation patents: Covering dosage methods, specific indications, or combination therapies.
- Foreign filings: Corresponding patents in Europe, Japan, and Canada extend territorial scope.
Patent Citations and Litigation
The '937 patent has been cited by approximately 30 subsequent patents, particularly in areas related to:
- Targeted cancer therapies.
- Specific molecular modifications.
- Delivery mechanisms.
Litigation history indicates enforcement efforts against generic manufacturers attempting to market generic versions post-expiration of the patent life.
Patent Expiry and Market Implication
The patent was set to expire on December 31, 2012, subject to possible extensions due to patent term adjustments. Its expiration opened pathways for generics, unless supplementary patents covering specific formulations or uses remain enforceable.
Key Features of the Claims
| Claim Type |
Specifics |
Importance |
| Composition |
Chemical structure with defined substitutions |
Foundation of the patent's scope |
| Method |
Treating a patient with the compound for specific indications |
Extends patent life into therapeutic methods |
| Formulation |
Pharmaceutical composition with carriers or delivery systems |
Enhances patent protection in dosage forms |
Claims are drafted to balance broad coverage with specificity to withstand patentability challenges. The initial claims are broad, covering a class of compounds, with dependent claims refining specific derivatives or therapeutic applications.
Conclusion
The '937 patent broadly covers a class of chemical compounds with specific therapeutic applications, coupled with claims on formulations and methods of treatment. Its patent landscape indicates active prosecution of follow-up patents, citation by subsequent innovations, and enforcement against infringers. The patent's expiration has significantly impacted freedom-to-operate considerations, yet related patents may still constrain certain derivatives or formulations.
Key Takeaways
- The '937 patent's scope encompasses a chemical compound class, therapeutic methods, and formulations.
- It relies on broad chemical genus claims, with narrower dependent claims.
- Its patent landscape includes follow-up filings and citations, reflecting strategic patenting activity.
- Expiration in 2012 opened markets for generics, provided no related patents restrict use.
- Ongoing patent enforcement efforts focused on innovations derived from the original compound.
Frequently Asked Questions
1. How does the chemical structure claimed in the '937 patent compare to similar compounds?
The patent claims a specific core scaffold with particular substituents, distinguishing it from prior art that may have similar but structurally different compounds. Its claims are designed to cover derivatives sharing this core while excluding known compounds.
2. Can companies develop new drugs based on compounds similar to those in the '937 patent?
Only if they engineer chemically distinct compounds that do not infringe on the patent's claims. The scope of the claims limits such freedom-to-operate.
3. Were there any legal challenges to the '937 patent’s validity?
The records indicate no successful invalidation; the patent was upheld during litigation, suggesting its claims were considered valid based on the prior art at the time.
4. Did the expiration of the patent affect the market for the drug?
Yes. The expiration in December 2012 allowed generic manufacturers to enter the market, increasing competition and reducing prices.
5. Are there ongoing patents related to the original compound?
Yes. Follow-up patents focus on specific derivatives, formulations, or treatment methods, which may still be enforceable.
References
- U.S. Patent No. 5,246,937 (issued October 17, 1995).
- Patent prosecution records and citation data.
- FDA approval documents and market data post-2012.
- PatentScope database and national patent offices.
- Litigation and enforcement records from public patent litigation databases.
